Overview

A Phase 1, Drug-Drug Interaction Study to Evaluate Safety, Tolerability, and Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adults

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

Phase:

Phase 1

Details

Lead Sponsor:

Global Alliance for TB Drug Development

Treatments:

Digoxin
Dolutegravir
Lamivudine
Midazolam
Tenofovir